Key Highlights:

  • Lunai Bioworks shares fell 43.11% to $0.2674 on Friday, October 23, 2026.
  • The company disclosed a Nasdaq staff determination to delist its stock on October 22, 2026.
  • Stockholders' deficit was $9,024,946 at June 30, 2026, against a $2.5 million minimum equity requirement.
  • Nasdaq trading is expected to be suspended on October 30, 2026, with delisting effective on or about November 12.
  • The company said it does not intend to arrange over-the-counter quotation after the suspension.

Lunai Bioworks Delisting: Why Did the Penny Stock Fall 43%?

Lunai Bioworks (NASDAQ:LNAI) shares fell 43.11% to $0.2674 on Friday, October 23, 2026, the session after the company disclosed that it will leave Nasdaq. The prior close was about $0.47 (calculated). The move followed a letter the company received on October 21 and a press release dated October 22.

Nasdaq staff determined to delist the stock because the company no longer meets the minimum stockholders' equity requirement under Nasdaq rule 5550(b)(1). The company also fails the alternative market value and net income standards, and it was already subject to a mandatory hearings panel monitor.

The board approved a voluntary withdrawal from Nasdaq on October 22 and said it will not request a hearing to contest the determination.

Trading Suspension and Delisting Dates: What Happens to Shareholders?

Nasdaq trading is expected to be suspended at the open on October 30, 2026. The company expects to file a Form 25 on or about November 2, and the delisting is expected to take effect on or about November 12.

After that, the company intends to file a Form 15 to suspend its reporting obligations with the SEC, if it is eligible. The company said it does not intend to arrange over-the-counter quotation and cannot assure that any trading market will exist after the suspension.

Balance Sheet Pressure: How Far Below the Equity Requirement Is Lunai Bioworks?

The company reported a stockholders' deficit of $9,024,946 for the fiscal year ended June 30, 2026. Against the $2.5 million minimum equity requirement, the shortfall is about $11.5 million (calculated).

Share price pressure had already led to two reverse stock splits. A 1-for-10 split took effect on September 30, 2025, and a 1-for-8 split took effect on May 22, 2026, which reduced shares outstanding from about 36.3 million to about 4.5 million at the time. The May split was aimed at regaining compliance with the $1.00 minimum bid price rule for the Nasdaq Capital Market.

Even after those splits, the stock closed at about $0.47 before Friday's drop (calculated), well below that $1.00 threshold.

Business Background: What Does Lunai Bioworks Do?

Lunai Bioworks, based in Sacramento, California, describes itself as an artificial intelligence-driven life sciences company focused on drug discovery and chemical defense. It combines clinical data, machine learning and in vivo validation to develop precision therapeutics.

Its stated focus areas are central nervous system diseases and oncology. The company has not announced a clinical readout or financing alongside the delisting plan, and the latest release does not provide a cash balance or revenue figure.

What to Watch Next: Can Lunai Bioworks Maintain a Market for Its Shares?

The takeaway is that the move reflects a structural change in how the shares can trade rather than a new clinical or commercial development. The next dated checkpoint is October 30, 2026, when Nasdaq trading is expected to be suspended, followed by the Form 25 filing around November 2 and the delisting around November 12. Any later announcement on quotation or SEC reporting will determine whether a trading market continues.

The company disclosed a Nasdaq delisting determination and a board decision to withdraw voluntarily, and shares fell 43.11% to $0.2674.

Trading is expected to be suspended on October 30, 2026, with delisting effective on or about November 12.

The company said it does not intend to arrange over-the-counter quotation and cannot assure that any market will exist.